Related Experiment Videos

The indication and effectiveness of low-dose erythromycin therapy in pediatric patients with bronchial asthma

Seigo Korematsu1, Kyoko Yamamoto, Tomokazu Nagakura

  • 1Department of Pediatrics and Child Neurology, Oita University, Oita, Japan. kseigo@med.oita-u.ac.jp

Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology
|June 16, 2010
PubMed

Insights

Low-dose erythromycin (EM) therapy improves severe pediatric asthma by reducing interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) levels. This treatment also stabilizes theophylline levels, enhancing symptom control in difficult-to-treat cases.

Area of Science:

  • Pediatric Pulmonology
  • Clinical Immunology
  • Pharmacology

Background:

  • Intractable pediatric bronchial asthma presents significant treatment challenges.
  • Standard therapies may be less effective in severe cases, necessitating exploration of alternative mechanisms.
  • Elevated chemokine and angiogenic factor levels are implicated in asthma severity.

Purpose of the Study:

  • To investigate the role of serum interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) in pediatric bronchial asthma severity.
  • To evaluate the efficacy of low-dose erythromycin (EM) in managing intractable pediatric asthma.
  • To assess the impact of low-dose EM on chemokine levels and theophylline pharmacokinetics.

Main Methods:

  • Serum IL-8 and VEGF levels were measured in 55 pediatric asthma patients.
  • Patients were categorized by asthma severity and received standard treatments.
  • Low-dose EM therapy was administered to severe cases, and clinical symptoms, chemokine levels, and theophylline concentrations were monitored over 6 months.

Main Results:

  • Higher serum IL-8 and VEGF levels correlated with more severe pediatric asthma.
  • Low-dose EM therapy significantly improved clinical symptoms in severe asthma patients.
  • EM treatment led to a marked decrease in IL-8 and VEGF levels and stabilized serum theophylline concentrations, reducing peak-trough fluctuations.

Conclusions:

  • IL-8 and VEGF are key factors contributing to the severity and resistance to standard therapies in intractable pediatric asthma.
  • Low-dose EM therapy is effective in improving pediatric asthma symptoms by suppressing IL-8 and VEGF.
  • EM enhances the efficacy of theophylline by maintaining stable serum levels, offering a novel therapeutic approach.

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...